M Holdings Securities Inc. Makes New $2.78 Million Investment in Stryker Corporation $SYK

M Holdings Securities Inc. acquired a new stake in Stryker Corporation (NYSE:SYK) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,110 shares of the medical technology company’s stock, valued at approximately $2,784,000.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Gables Capital Management Inc. bought a new position in Stryker during the second quarter worth about $25,000. Kilter Group LLC acquired a new position in shares of Stryker during the 2nd quarter worth about $25,000. Cornerstone Financial Management LLC grew its position in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after buying an additional 31 shares during the period. Highland Investment Advisors LLC bought a new stake in shares of Stryker in the 2nd quarter valued at about $25,000. Finally, Compass Financial Management LLC bought a new stake in shares of Stryker in the 2nd quarter valued at about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Down 0.2%

SYK stock opened at $325.26 on Monday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. The stock has a market capitalization of $123.83 billion, a P/E ratio of 34.64, a P/E/G ratio of 2.24 and a beta of 0.78. Stryker Corporation has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The business has a 50-day moving average of $292.37 and a 200-day moving average of $323.59.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to the consensus estimate of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.74%. The company’s revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.19 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 14.84 earnings per share for the current fiscal year.

Insider Transactions at Stryker

In other news, insider Dylan Crotty sold 441 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 300,000 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. The trade was a 11.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 351,267 shares of company stock valued at $118,197,701 in the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SYK. Royal Bank Of Canada cut their price target on shares of Stryker from $420.00 to $375.00 and set an “outperform” rating on the stock in a research report on Friday, October 30th. Jefferies Financial Group decreased their price objective on shares of Stryker from $440.00 to $405.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. Citizens Jmp lowered their target price on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating for the company in a research note on Friday, October 30th. Rothschild & Co Redburn lowered their target price on shares of Stryker from $360.00 to $336.00 in a research note on Monday, November 2nd. Finally, Wells Fargo & Company cut their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a report on Wednesday, September 9th. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $343.73.

About Stryker

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings.

The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

Founded in 1941 by orthopedic surgeon Dr.